WHO
Second round of public submissions to WHO Expert Working Group on R&D Financing
Submitted by thiru on 17. November 2009 - 3:42November 17, 2009
KEI Comments to EWG 2nd Web-based Public Hearing: Defending the Status Quo, or Roadmap for Change?
Submitted by James Love on 6. September 2009 - 6:43On Saturday, KEI filed comments with the WHO EWG's 2nd web based hearing. Our comments focused on the criteria for new proposals.
WHO IGWG Negotiation
Submitted by Judit Rius on 1. September 2009 - 15:28Bring content from: http://www.keionline.org/content/view/3/1/
WHO Expert Working Group on R&D Financing (EWG)
Submitted by Staff on 1. September 2009 - 13:44WHO website on the EWG
NEWS: The EWG secretariat has released a draft evaluation framework, evaluation criteria and the inventory of financing proposals. The EWG is accepting public comments through the Second Web-based Public Hearing. Deadline: September 5 2009. KEI has offered critical comments on the criteria.
WHO Negotiations on Public Health, Innovation and Intellectual Property
Submitted by KEI Staff on 25. August 2009 - 14:35In April 2006, WHO released a report by the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH Report).
Reform of World Health Organization
Submitted by James Love on 24. August 2009 - 9:16How to reform the WHO?
WHO releases sketchy report on second meeting of Expert Working Group on R&D Financing
Submitted by Staff on 30. June 2009 - 22:00The World Health Organization just published a report on this week’s second meeting of the WHO Expert Working Group (EWG) on R&D Financing.
US guts transparency clause in PAHO R&D resolution
Submitted by James Love on 25. June 2009 - 14:11The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.
The US opposed this language:
“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”
The US agreed to this language:
PAHO dispute over standards for transparency of economic data for pharmaceutical industry
Submitted by James Love on 25. June 2009 - 10:49Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:
